Instead, one study looked at IL-17A/IL-22 production by FluoroSpot assays of Spike peptide-pulsed PBMCs in patients with psoriasis undergoing various treatments after a single BNT162b2 mRNA vaccine dose, showing the low production of such cytokines in psoriasis patients undergoing anti-TNF therapy (including methotrexate and anti-IL-17 and anti-IL-23 therapies), similar to healthy controls [86]. Here, IL17A is linked to psoriasis.